Name: Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements
Creator: FinSpry

Zentalis Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Zentalis Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	67.43	0.90	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	67.43	0.90	0.00	0.00	0.00
Operating Expenses
Research & Development	167.77	189.59	172.73	175.60	84.90
Selling, General & Administrative	87.12	64.35	54.55	40.94	33.89
Operating Expenses	254.88	253.94	227.29	216.54	118.79
Operating Income	-187.46	-253.94	-227.29	-216.54	-118.79
Other Income/Expense
Interest Income	12.27	9.46	2.26	1.31	1.24
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	21.77	-22.95	5.99	-49.75	0.00
Income
Income Before Tax	-165.69	-276.89	-221.30	-164.56	-118.10
Income Tax Expense	0.18	-0.60	-0.47	-0.30	0.44
Net Income	-165.84	-292.19	-236.81	-158.73	-117.84
Net Income - Continuous Operations	-165.87	-292.31	-237.11	-166.09	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-186.17	-252.55	-225.86	-216.00	-118.63
EBIT	-187.46	-253.94	-227.29	-216.54	-118.79
Depreciation & Amortization	1.29	1.39	1.40	0.50	0.16
Earnings Per Share
Basic EPS	-2.00	-4.00	-4.00	-4.00	-4.00
Diluted EPS	-2.00	-4.00	-4.00	-4.00	-4.00
Basic Shares Outstanding	71.08	65.41	52.86	42.69	28.11
Diluted Shares Outstanding	71.08	65.41	52.86	42.69	28.11